MYOC and glaucoma: Non-viral CRISPR-Cas9 mRNA delivery edits mutant MYOC, alleviates ER stress, and reverses ocular hypertension in myocilin glaucoma, offering a safe, one-time therapeutic strategy beyond viral vectors.